CS
YMAB

Candriam SCA’s Y-mAbs Therapeutics YMAB Stock Holding History

Candriam SCA’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-172,584
Closed -$2.49M – 892
2022
Q3 		$2.49M Hold
172,584
– – 0.02% 537
2022
Q2 		$2.61M Hold
172,584
– – 0.02% 445
2022
Q1 		$2.05M Sell
172,584
-11,108
-6% -$114K 0.01% 534
2021
Q4 		$2.98M Buy
183,692
+5,511
+3% +$118K 0.02% 469
2021
Q3 		$5.08M Hold
178,181
– – 0.03% 396
2021
Q2 		$9.26M Sell
178,181
-1,764
-1% -$56.6K 0.06% 298
2021
Q1 		$8.56M Sell
179,945
-1
-0% -$41 0.07% 275
2020
Q4 		$8.91M Sell
179,946
-2,758
-2% -$128K 0.07% 282
2020
Q3 		$7.01M Buy
182,704
+17,707
+11% +$705K 0.07% 295
2020
Q2 		$7.13M Buy
164,997
+107,451
+187% +$4.06M 0.08% 273
2020
Q1 		$1.76M Buy
57,546
+20
+0% +$581 0.02% 552
2019
Q4 		$1.8M Buy
+57,526
New +$1.7M 0.02% 569

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Candriam SCA's YMAB Position: Q4 2022 in Review

Candriam SCA sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 172,584 shares — an estimated $2.49M sold.

Candriam SCA first reported a position in YMAB in Q4 2019 and held it in 12 quarters. The position peaked at $9.26M in Q2 2021. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • Candriam SCA reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Candriam SCA sold 172,584 Y-mAbs Therapeutics shares in Q4 2022, an estimated $2.49M.
  • Candriam SCA first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 12 quarters.
  • Candriam SCA's Y-mAbs Therapeutics position peaked at $9.26M in Q2 2021.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.